side effects upon conversion between the DR and ER formulations. It 3. Depakote ER (divalproex sodium extended release tablets) [package
Divalproex DR vs. Divalproex ER Divalproex DR (delayed-release) is the equivalent of Depakote. In this case delayed-release simply means
Conclusions: No difference in tolerability was found between Depakote DR and Depakote ER in elderly patients. Overnight conversion was tolerated
side effects upon conversion between the DR and ER formulations. 3. Depakote ER (divalproex sodium extended release tablets) [package insert].
for ER Ave vs DR Ave. 0.57 . The primary test for Depakote ER was equivalent to 875 mg Depakote DR, and 1500 mg Depakote ER.
Hair loss is possible with Depakote and Depakote ER. This side effect was common in clinical trials of Depakote DR tablets, Depakote ER tablets, and Depakote DR sprinkle capsules.
Depakote DR tablets. A dose conversion table is provided in the label for conversion from Depakote DR to Depakote. ER tablets based on the
Conclusions: No difference in tolerability was found between Depakote DR and Depakote ER in elderly patients. Overnight conversion was tolerated
Conversion from immediate release to DR or 24-hour ER: Refer to adult dosing. Conversion from DR to 24-hour ER: Refer to adult dosing. Conversion to IV valproate preparations: Refer to adult dosing. Dosing: Pediatric. Note: Use of Depakote ER in pediatric patients 10 years of age is not recommended; do not confuse Depakote ER with Depakote.
Comments